Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Histopathologic regression in patients with primary cutaneous melanoma undergoing sentinel lymph node biopsy is associated with favorable survival and, after metastasis, with improved progression-free survival on immune checkpoint inhibitor therapy:...
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Author(s): Wagner, Nikolaus B.; Knierim, Sarah M.; Luttermann, Felix; Metzler, Gisela; Yazdi, Amir S.; Bauer, Jürgen; Gassenmaier, Maximilian; Forschner, Andrea; Leiter, Ulrike; Amaral, Teresa; Garbe, Claus; Eigentler, Thomas K.; Forchhammer, Stephan; Flatz, Lukas
- Source:
Journal of the American Academy of Dermatology; Apr2024, Vol. 90 Issue 4, p739-748, 10p
- Additional Information
- Abstract:
Histopathologic regression of cutaneous melanoma is considered a favorable prognostic factor, but its significance in clinical practice remains controversial. To investigate the prognostic importance of regression in patients with primary cutaneous melanoma undergoing sentinel lymph node (SLN) biopsy and to assess its significance in patients progressing to an unresectable stage requiring systemic therapy. We retrospectively reviewed patients with newly diagnosed melanoma undergoing SLN biopsy between 2010 and 2015 and available information on histopathologic regression (n = 1179). Survival data and associations of clinical variables with SLN status were assessed. Patients with regressive melanoma showed favorable relapse-free (hazard ratio [HR], 0.52; P =.00013), distant metastasis–free (HR, 0.56; P =.0020), and melanoma-specific survival (HR, 0.35; P =.00053). Regression was associated with negative SLN (odds ratio, 0.48; P =.0077). In patients who progressed to an unresectable stage, regression was associated with favorable progression-free survival under immune checkpoint inhibition (HR, 0.43; P =.031) but not under targeted therapy (HR, 1.14; P =.73) or chemotherapy (HR, 3.65; P =.0095). Retrospective, single-institutional design. Regression of cutaneous melanoma is associated with improved prognosis in patients eligible for SLN biopsy as well as in patients with unresectable disease receiving systemic therapy with immune checkpoint inhibitors. [ABSTRACT FROM AUTHOR]
- Abstract:
Copyright of Journal of the American Academy of Dermatology is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
No Comments.